Plain-English translation of NCT06778317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying a blood test called mSEPT9 that looks for early warning signs of liver cancer in people who have cirrhosis. Researchers want to see if this test can reliably predict who might develop liver cancer in the future, so doctors can watch high-risk patients more closely. The study will follow 400 people with cirrhosis (but no liver cancer yet) for five years, collecting blood samples every six months.
Right now, doctors don't have a reliable, simple way to predict which cirrhosis patients will develop liver cancer. This medication aims to fill that gap by offering a non-invasive blood test that could help doctors catch liver cancer earlier and personalize care for each patient based on their individual risk.
You likely qualify if…
You likely don't qualify if…
You will visit the study center every six months for five years. At each visit, you'll have standard medical check-ups, blood tests, and imaging scans as part of your normal cirrhosis care—plus an extra blood sample for the mSEPT9 test. The study team will track whether you develop liver cancer during this time. Your test results won't change your regular treatment during the study, but they'll help researchers understand how well the blood test predicts liver cancer risk.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
France